Amylx Pharmaceuticals Inc vs D Wave Quantum Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while D Wave Quantum Inc trades at $20.66 (market cap $7.53B). The key difference: D Wave Quantum Inc is far larger — about 2.9× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | QBTS | |
|---|---|---|
Market Cap | $2.64B | $7.53B |
Sector | Health | Technology |
52-Week High | $24.19 | $44.78 |
52-Week Low | $7.82 | $12.98 |
Enterprise Value | $2.39B | $7.04B |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.35, up 3.0% today, with a bullish technical signal from moving averages. The company reported a net loss of $144.74M in 2025, with negative ROE and ROA, but maintains a strong cash position of $250.8M extending into 2028. Key near-term catalyst is the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, which could drive significant stock movement.
The investment case hinges on successful clinical outcomes; a positive readout may support the consensus price target of $30.00, but persistent losses and high P/B ratio of 11.02 pose risks. Analyst sentiment is overwhelmingly bullish with 91% buy ratings, though recent earnings misses highlight execution challenges.
D-Wave Quantum (QBTS) trades at $20.75, up 2.77% today, but faces bearish technical signals amid mixed earnings performance. The company reported a Q2 2026 loss of $0.10 per share, missing estimates, while revenue remained flat at $3.1 million. Despite negative profitability metrics, analyst consensus remains unanimously bullish with a $38.29 price target, reflecting optimism about quantum computing adoption and strong bookings growth.
The stock presents high-risk speculative potential with significant valuation concerns trading at 584x sales. While institutional interest and government funding support long-term quantum computing prospects, persistent losses and declining revenue create substantial execution risk. Investors must weigh Wall Street optimism against fundamental weaknesses in this emerging technology play.
Trailing returns across standard periods
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →